NMPA approves IND for HLX48 clinical trial in patients with advanced solid tumors
Shanghai Henlius Biotech, Inc. (2696.HK) announced that its independently developed c-Met/EGFR bispecific antibody–drug conjugate (ADC), HLX48 for injection, has been approved by the National Medical Products Administration (NMPA), for the treatment of advanced and metastatic solid tumors. Recently, it has received approval from the Human Research Ethics Committee (HREC) in Australia and been acknowledged by the Therapeutic Goods Administration (TGA). To accelerate the evaluation of HLX48’s preliminary efficacy and safety in humans, the company plans to initiate multi-regional clinical trials (MRCT) simultaneously in China, Australia, and other regions to evaluate HLX48’s safety, tolerability, and preliminary efficacy in patients with advanced solid tumors.
Share:
More News
“The initial efficacy data from the Part C studies are consistent with the encouraging efficacy signals we previously reported for Parts A and B of THIO-101, including an 88% disease control rate in third-line NSCLC patients. This measure of efficacy is close to triple the reported outcome for standard-of-care chemotherapy
“Patients with non-muscle invasive bladder cancer continue to face a significant risk of disease recurrence despite available treatment options,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “UGN-501 is an investigational next-generation oncolytic virus designed to selectively destroy tumor cells while generating an anti-tumor immune response. FDA clearance of
“Whitehawk has established strong expertise in ADC technology and oncology drug development,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This collaboration further expands the application of Biocytogen’s fully human bispecific antibodies in ADC development. We look forward to supporting the efficient advancement of multiple programs by contributing high-quality
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The AZUR-1 results support the potential for dostarlimab to transform treatment for dMMR/MSI-H locally advanced rectal cancer. For many patients today, rectal cancer treatment comes with the tolerability burden and lasting impacts from chemotherapy, radiation and surgery. These data